MA51297B1 - Quinazolinones as parp14 inhibitors - Google Patents
Quinazolinones as parp14 inhibitorsInfo
- Publication number
- MA51297B1 MA51297B1 MA51297A MA51297A MA51297B1 MA 51297 B1 MA51297 B1 MA 51297B1 MA 51297 A MA51297 A MA 51297A MA 51297 A MA51297 A MA 51297A MA 51297 B1 MA51297 B1 MA 51297B1
- Authority
- MA
- Morocco
- Prior art keywords
- quinazolinones
- parp14
- inhibitors
- parp14 inhibitors
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La présente invention concerne des quinazolinones et des composés apparentés qui sont des inhibiteurs de parp14 et sont utiles, par exemple, dans le traitement du cancer et de maladies inflammatoires.The present invention relates to quinazolinones and related compounds which are inhibitors of parp14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608747P | 2017-12-21 | 2017-12-21 | |
PCT/US2018/066700 WO2019126443A1 (en) | 2017-12-21 | 2018-12-20 | Quinazolinones as parp14 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MA51297A MA51297A (en) | 2020-10-28 |
MA51297B1 true MA51297B1 (en) | 2023-01-31 |
Family
ID=71842911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA51297A MA51297B1 (en) | 2017-12-21 | 2018-12-20 | Quinazolinones as parp14 inhibitors |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR114003A1 (en) |
MA (1) | MA51297B1 (en) |
-
2018
- 2018-12-20 AR ARP180103771A patent/AR114003A1/en unknown
- 2018-12-20 MA MA51297A patent/MA51297B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR114003A1 (en) | 2020-07-08 |
MA51297A (en) | 2020-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52486B1 (en) | Pyridazinones used as parp7 inhibitors | |
MA45029A (en) | ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR CANCER TREATMENT | |
MA43169B1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
PH12019500204A1 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
EA201891268A1 (en) | COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS | |
MA41060B1 (en) | Compositions comprising bacterial strains | |
MA55434A (en) | COMPOSITIONS COMPRISING BACTERIAL STRAINS | |
MA43335B1 (en) | Transthyretin (ttr) arni compositions and methods for use thereof for the treatment or prevention of diseases associated with ttr | |
MA39193B1 (en) | Gpr6 modulators based on tetrahydropyridopyrazines | |
EA202091709A1 (en) | DNA PC INHIBITORS | |
MA41010B1 (en) | Compositions comprising bacterial strains | |
MX2020006365A (en) | Quinazolinones as parp14 inhibitors. | |
FR3021970B1 (en) | ANTIBODY AGAINST GALECTIN 9 AND INHIBITOR OF THE SUPPRESSIVE ACTIVITY OF T REGULATORY LYMPHOCYTES | |
AR119389A1 (en) | INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES | |
EA202091708A1 (en) | DNA PC INHIBITORS | |
MA47736B1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
EA201891468A1 (en) | COMPOSITIONS AND METHODS TO REDUCE TAU EXPRESSION | |
EA201892714A1 (en) | IMIDAZOLINE CONNECTIONS AS ELASTASY HUMAN NEUTROPHIL INHIBITORS | |
MA52920B1 (en) | Compositions and methods relating to pyridinoylpiperidine 5-ht1f agonists | |
EA201791937A1 (en) | ANTI-INFLAMMATORY POLYPEPTIDES | |
EA202090944A1 (en) | ANTI-CD3-ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING ONCOLOGICAL DISEASES, CONTAINING IT | |
MA51297B1 (en) | Quinazolinones as parp14 inhibitors | |
EA202091524A1 (en) | INHIBITORS OF THE PROTEASE 2 ACTIVATED RECEPTOR | |
EA202091542A1 (en) | QUINAZOLINONES AS PARP14 INHIBITORS | |
EA201990393A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 USED FOR TREATING VARIOUS DISEASES AND DISORDERS |